Federated Hermes Inc. Grows Stock Holdings in GSK PLC Sponsored ADR (NYSE:GSK)

Key Points

• Federated Hermes Inc. has increased its holdings in GSK PLC by 51.3% in the first quarter, now owning 137,814 shares valued at approximately $5.34 million.
• GSK's recent earnings report showed an earnings per share (EPS) of $1.23, exceeding analyst expectations and reflecting a year-over-year revenue growth of 1.3%.
• The company announced a quarterly dividend of $0.4206, resulting in an annualized yield of 4.5%, despite a relatively high dividend payout ratio of 79.17%.

Federated Hermes Inc. lifted its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 51.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 137,814 shares of the pharmaceutical company's stock after acquiring an additional 46,715 shares during the period. Federated Hermes Inc.'s holdings in GSK were worth $5,339,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. FMR LLC boosted its holdings in GSK by 82.1% in the 4th quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock worth $1,786,475,000 after acquiring an additional 23,814,104 shares during the period. Voloridge Investment Management LLC lifted its position in shares of GSK by 1,360.4% during the fourth quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock worth $73,222,000 after purchasing an additional 2,016,795 shares in the last quarter. Bridgewater Associates LP boosted its stake in shares of GSK by 132.7% in the fourth quarter. Bridgewater Associates LP now owns 2,247,691 shares of the pharmaceutical company's stock valued at $76,017,000 after purchasing an additional 1,281,855 shares during the period. Woodline Partners LP purchased a new position in shares of GSK in the fourth quarter valued at $36,665,000. Finally, Miller Howard Investments Inc. NY grew its holdings in GSK by 138.4% during the 1st quarter. Miller Howard Investments Inc. NY now owns 1,646,791 shares of the pharmaceutical company's stock valued at $63,797,000 after purchasing an additional 955,891 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Trading Up 1.0%

NYSE GSK opened at $37.53 on Monday. The company has a market capitalization of $76.57 billion, a price-to-earnings ratio of 17.38, a price-to-earnings-growth ratio of 1.64 and a beta of 0.51. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. GSK PLC Sponsored ADR has a 12 month low of $31.72 and a 12 month high of $44.67. The company's fifty day moving average price is $38.96 and its two-hundred day moving average price is $37.73.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. The business had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The company's revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.43 EPS. As a group, research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be given a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.5%. GSK's dividend payout ratio (DPR) is presently 79.17%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on GSK shares. BNP Paribas began coverage on shares of GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective on the stock. Hsbc Global Res raised GSK to a "strong sell" rating in a research report on Monday, April 28th. Berenberg Bank reissued a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Finally, Wall Street Zen upgraded GSK from a "hold" rating to a "buy" rating in a research note on Sunday. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, GSK presently has an average rating of "Hold" and an average price target of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.